Table 2.

Transplantation outcome of the 83 patients with DDX41mut patients

OutcomesAll patients (N = 83)AML (n = 64)MDS (n = 19)
Estimation (95% CI)Estimation (95% CI)Estimation (95% CI)
Median FU, y 4.7 (3.4-5.9) 4.8 (3.4-6.5) 3.9 (1.9-5.9) 
OS (2 years) 73.9 (62.8-82.1) 72.7 (59.7-82.1) 78 (51.5-91.1) 
LFS (2 years) 68.9 (57.5-77.8) 71.2 (58.3-80.8) 61.3 (35.5-79.3) 
RI (2 years) 10.2 (4.7-18.1) 6.5 (2.1-14.7) 22.3 (6.6-43.7) 
NRM (2 years) 21 (12.8-30.5) 22.2 (12.8-33.2) 16.4 (3.8-36.9) 
aGVHD-II/IV (100 days) 28 (18.8-38.1) 25.4 (15.4-36.7) 36.8 (15.9-58.1) 
aGVHD-III/IV (100 days) 14.6 (8-23.2) 12.7 (5.9-22.2) 21.1 (6.3-41.6) 
cGVHD (2 years) 39.2 (28.2-50.1) 37.9 (25.6-50) 43.7 (18.7-66.5) 
cGVHD Ext (2 years) 9.6 (4.2-17.7) 6.9 (2.2-15.4) 18.8 (4.3-41.3) 
OutcomesAll patients (N = 83)AML (n = 64)MDS (n = 19)
Estimation (95% CI)Estimation (95% CI)Estimation (95% CI)
Median FU, y 4.7 (3.4-5.9) 4.8 (3.4-6.5) 3.9 (1.9-5.9) 
OS (2 years) 73.9 (62.8-82.1) 72.7 (59.7-82.1) 78 (51.5-91.1) 
LFS (2 years) 68.9 (57.5-77.8) 71.2 (58.3-80.8) 61.3 (35.5-79.3) 
RI (2 years) 10.2 (4.7-18.1) 6.5 (2.1-14.7) 22.3 (6.6-43.7) 
NRM (2 years) 21 (12.8-30.5) 22.2 (12.8-33.2) 16.4 (3.8-36.9) 
aGVHD-II/IV (100 days) 28 (18.8-38.1) 25.4 (15.4-36.7) 36.8 (15.9-58.1) 
aGVHD-III/IV (100 days) 14.6 (8-23.2) 12.7 (5.9-22.2) 21.1 (6.3-41.6) 
cGVHD (2 years) 39.2 (28.2-50.1) 37.9 (25.6-50) 43.7 (18.7-66.5) 
cGVHD Ext (2 years) 9.6 (4.2-17.7) 6.9 (2.2-15.4) 18.8 (4.3-41.3) 

Ext, extensive; FU, follow-up; RI, relapse incidence.

or Create an Account

Close Modal
Close Modal